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 Abstract 26 
Uroguanylin is a peptide gut hormone proposed to have a role in signalling post meal satiety. 27 
Uroguanylin circulates as its pro-hormone, prouroguanylin. There has been limited investigation of the 28 
regulation of prouroguanylin by food; therefore we investigated prouroguanylin regulation following 29 
meals. In separate experiments we investigated the effects of high calorie (1451 kcal) and medium 30 
calorie (725 kcal), high fat meals, on plasma prouroguanylin concentrations.  We then examined the 31 
effect of a 722.5 kcal high carbohydrate breakfast on prouroguanylin concentrations, comparing the 32 
response in healthy weight adults versus those who are overweight/ with obesity. The 1451 kcal meal 33 
increased prouroguanylin concentrations, versus fasting at 60 (P<0.05), 90 (P<0.01) and 120 (P<0.001) 34 
minutes. After the 725 kcal meal hormone concentrations rose more slowly and were significant versus 35 
fasting concentrations at 120 minutes (P<0.01). The high carbohydrate breakfast 722.5 kcal, led to an 36 
initial suppression of hormone concentrations at 30 mins post meal (P<0.05) followed by an increase 37 
in concentrations until they were significant versus fasting at 120 mins (P<0.01). Participants 38 
overweight/ with obesity had lower fasting prouroguanylin concentrations (P<0.05), but post meal 39 
concentrations did not differ between the groups. Our results suggest there is a delayed increase in 40 
prouroguanylin concentrations following, large and regular sized mixed macronutrient meals rich in fat 41 
or carbohydrate. Fasting levels are suppressed in people who are  overweight/ with obesity, but the post 42 








1. Introduction 51 
Hormones secreted from the gastrointestinal system (gut hormones) are essential regulators of appetite 52 
and satiety (1).  Pharmacological (2) and dietary (3)(4) innovations are targeting the release of these 53 
hormones for the treatment of obesity.   54 
Uroguanylin is a peptide ligand of the Guanylyl cyclase C receptor (GUCY2C). It is highly expressed 55 
in the proximal intestine, and in particular the enterochromaffin cells (5). However, in humans there is 56 
some debate over the cell type expressing uroguanylin; one study found expression in the human 57 
duodenum, but suggested the cells expressing uroguanylin were not enterochromaffin cells (6). In 58 
addition to the small intestine uroguanylin is also expressed in the colon (6)(7).  Within the gut 59 
uroguanylin has paracrine actions, activating GUCY2C to regulate electolyte and fluid balance (8), and 60 
uroguanylin and GUCY2C have been targeted to treat gastrointestinal disorders including, constipation 61 
(9) and irritable bowel syndrome (10). There is also evidence uroguanylin acts outside the gut to regulate 62 
electrolyte and fluid balance (8).  More recently uroguanylin has been proposed as a novel appetite and 63 
body mass regulating gut hormone (11). Valentino et al.’s (11) studies suggested prouroguanylin 64 
(precursor of uroguanylin) is secreted into circulation after a meal and is processed to active uroguanylin 65 
in the hypothalamus where it signals satiety (11). In support of this hypothesis, in their study transgenic 66 
mice lacking GUCY2C receptor are hyperphagic and developed obesity (11). Subsequent studies in 67 
mice have supported some aspects of Valentino’s work and challenged others (12)(13)(14)(15)(16).  A 68 
study using knockout models found loss of uroguanylin, but not GUCY2C, led to increased body mass 69 
and adiposity, and central administration of GUCYC agonists had no affect on feeding (12). While 70 
another study reported chronic central infusion of uroguanylin led to increased body mass and adiposity, 71 
but this effect was not mediated by chronic increased feeding (13). However, they did observe an acute 72 
effect of urogunaylin on feeding in the first few hours after injection. In contrast a very recent study 73 
found neither administration or upregulating the expression of either uroguanylin or prouroguanylin 74 
had any effect on feeding or glucose homeostasis (16). Yet two other studies have reported uroguanylin 75 
levels are effected by diet, leptin and obesity(14)(15). In summary, most, but not all rodent studies do 76 
support a role for uroguanylin in the regulation of body mass, but effects on feeding and glucose 77 
homeostasis remain controversial. 78 
There  have been limited further studies of uroguanylin regulation  in humans. Of note, a recent study 79 
(17) suggested fasting prouroguanylin concentrations are lower in people with obesity and rise 80 
following Roux-en-Y gastric bypass (RYGB), a pattern similar to is observed with glucagon like 81 
peptide -1 (GLP-1) and peptide YY (PYY) (18). In support of this another study reported an 82 
upregulation of uroguanylin mRNA following RYGB (16). A further recent study also reported female 83 
adolescents with obesity had lower fasting concentrations of prouroguanylin than those who did not 84 
have obesity, but post meal changes in prouroguanylin were similar in both groups (19). However, there 85 
has been limited work to elucidate the factors influencing the release of prouroguanylin as a post meal 86 
signal of satiety in adults. Valentino (11) and colleagues only investigated prouroguanylin release 87 
following a single large (1460 kcal) mixed macronutrient meal in healthy weight adult male volunteers,  88 
while Di Guglielmo et al. (19) studied prouroguanylin following a single meal in adolescents. To begin 89 
to understand prouroguanylin release in response to a meal we aimed to determine the effects of smaller 90 
meals more typical of the energy intake of real life single meals on circulating prouroguanylin 91 
concentrations, and to see if fasting and post meal concentrations of prouroguanylin differed between 92 








2. Methods 101 
2.1 Ethics and Recruitment 102 
All studies were performed according to the principles of the Declaration of Helsinki and were approved 103 
by the local research ethics committee at the University of Roehampton. Participants were recruited via 104 
posters displayed in the University of Roehampton. For all studies we recruited healthy volunteers over 105 
the age of 18.  Participants with Diabetes, gastrointestinal conditions/diseases or food allergies were 106 
excluded.  For studies 1 and 2 we recruited males with a BMI between 18 and 30 kg/m2 to allow 107 
comparisons to the previous study (11).  For study 3 we recruited both sexes with a minimum BMI of 108 
18 kg/m2   and aimed to have a similar number of participants with BMIs under and over 25 kg/m2. 109 
Females who were pregnant, lactating or having given birth in the past year were excluded. 110 
2.2 Study 1-  The effect of a large 1451 kcal meal on plasma Prouroguanylin concentrations in 111 
males  112 
Seven healthy male participants fasted overnight (12hours) then consumed a 1451 kcal meal of similar 113 
composition to sausage and egg breakfast meal given by Valentino et al., 2011 (11). Finger prick blood 114 
samples were taken and plasma extracted for prouroguanylin measurement (as described below) fifteen 115 
minutes before the breakfast (time 0 minutes) and at intervals up to 120 minutes after the meal (15 116 
minutes, 30 minutes, 60  minutes, 90 minutes, 120 minutes). Hunger levels were measured at all time 117 
points using a visual analogue scale.  118 
 119 
2.3 Study 2- The effect of a 725 kcal meal on plasma Prouroguanylin  concentrations in males 120 
Seven healthy male participants fasted overnight (12 hours) then consumed a 725 kcal meal with the 121 
same components as study 2, but half the portions. Finger prick blood samples were taken at the same 122 
timepoints and plasma extracted for prouroguanylin measurement. 123 
2.4 Study 3- The effect of a 722.5 kcal carbohydrate rich breakfast on plasma Prouroguanylin 124 
concentrations in males and females of a healthy weight and those who are overweight/ with 125 
obesity. 126 
Eighteen participants (10 male, 8 female) fasted overnight (12hours) then consumed a 722.5 kcal meal. 127 
Nine of the participants (3 female and 5 male) had a BMI over 25 kg/m2 and 9 under 25 kg/m2. Finger 128 
prick blood samples were taken and plasma extracted for prouroguanylin measurement as described for 129 
study 1 except blood samples were only taken fifteen minutes before the breakfast (time 0 minutes) and 130 
30 minutes, 60 minutes and 120 minutes post breakfast. These time points were chosen as the most 131 
important based on the results from studies 1 and 2. A decision was made to limit the time points for 132 
this study to minimise finger prick samples and therefore any discomfort to participants. This was both 133 
from an ethical point of view and to enhance recruitment. 134 
2.5 Composition of meals  135 
Contents of the meals were determined from food packaging if stated and estimated using Dietplan 7 136 
(Forestfield Software) when not stated. Full meal contents can be found in Table 1 and 2. For Study 1 137 
our target was to design a high calorie, unhealthy meal similar to the one used by Valentino et al.(11).  138 
However, some changes were made to accommodate for foods easily available, and regularly consumed 139 
for breakfast in the UK. The mixed macronutrient meal contained 1451 kcal and was 132 g carbohydrate 140 
(36.3% of the calories), 57 g protein (15.7% of the calories), 75 g fat (48% of the calories).  The meal 141 
used in study 2 was identical to the meal in study 1 except all portions were half the size (725 kcal, 142 
36.3%-66 g carbohydrate, 15.7%-29 g protein, 48%-3 8g fat). 143 
The high carbohydrate breakfast used in study 3 was designed to be closer to what may have been 144 
considered traditionally to be a healthy breakfast in the UK (20), while keeping the calorie content 145 
similar to study 2. The main components were fruit (apple, banana, dried apricot), muesli and orange 146 
juice. It contained 722.5 kcal and was 134.7 g (73.9% of the calories) carbohydrate, 24.5 g protein 147 
(13.4% of the calories), 10.3 g (12.7% of the calories) fat. The main difference compared to study 2 148 
was this meal had a much higher carbohydrate content and lower fat content. Given uroguanylin’s 149 
reported role in regulating fluid and salt balance (21)(22)(8), it is also important to note the high 150 
carbohydrate breakfast had a much lower sodium content (0.4 g versus study 1, 4.3 g and study 2, 2.15 151 
g). 152 
 153 
2.6 Sample collection and Prouroguanylin measurement 154 
Blood samples were collected using the finger prick method into Ethylenediaminetetraacetic acid 155 
(EDTA) tubes, gently mixed and put on ice. The finger tip was cleaned using an alcohol swab then skin 156 
punctured using a safety lance (Sarstedt, Germany), the finger was lightly pressed to start blood flow 157 
(if required), then up to 0.5ml blood (per sample) was collected using a capillary EDTA tube. Before 158 
processing the samples they were centrifuged at 3000g and plasma separated and stored at -20°C. 159 
Samples were stored at -20°C for no longer than 8 weeks before measurement.  Prouroguanylin 160 
concentrations were measured using an ELISA kit from BioVendor (Human Prouroguanylin ELISA, 161 
Cat. No. RD191069200R). The assay was performed according to the manufacturer’s instructions. This 162 
assay has previously been validated for measurement of prouroguanylin (23). Samples from each 163 
participant were measured consecutively and on the same ELISA plate.  The limit of detection was 86 164 
pg/ml and intra and inter- assay co-efficient of variation were 2.3% and 6.4% respectively. For study 3 165 
samples from participants with healthy weights and the participants who were overweight/with obesity 166 
were assayed in random order to minimise any effect of variation within the assay. 167 
2.7 Data Analysis 168 
For studies 1 and 2 a Repeated Measjures ANOVA was used with post hoc Dunnetts test to see if there 169 
was a difference between pre meal concentrations (time 0 minutes) and time points. To compare post 170 
meal changes from the meals given in study 1 and 2, percentage change from baseline (time 0 minutes) 171 
was calculated for each time point and comparisons made using Repeated Measures Two way ANOVA.  172 
For study 3 data from all participants were analysed by Repeated Measures ANOVA post hoc Dunnetts 173 
test. When data were split into two groups, data were analysed by Repeated Measures Two way 174 
ANOVA with post hoc Bonferroni test. To compare data from studies 2 and 3; males from study 3 with 175 
a BMI < 26 kg/m2  (the maximum BMI of any participant in study 2) were selected, and for each study 176 
percentage change from baseline (time 0 minutes) was calculated for each post meal time point and 177 
comparisons made using Repeated Measures Two way ANOVA with post hoc Bonferroni test.  Fasting 178 
and peak prouroguanylin concentrations from the 3 studies were analysed by independent t-test where 179 
applicable. All analysis was performed using Graphpad, Prism 6 (GraphPad Software, San Diego, CA) 180 
















3. Results 197 
3.1 Study 1- The effect of a large 1451 kcal meal on plasma Prouroguanylin concentrations in males                      198 
Seven males completed this study. The mean BMI was 23.4 kg/m2 ± 3.8 with a range between 19.8 and 199 
24.5 kg/m2. The mean age was 23.5 years with a range between 21-35 years. Following the meal there 200 
was a significant increase in mean plasma prouroguanylin concentrations at 60, 90 and 120 minutes 201 
(P<0.05, 0 minutes versus 60 minutes; P<0.01, 0 minutes versus 90 minutes; P<0.001, 0 minutes versus 202 
120 minutes) (Figure 1 A).  Prouroguanylin concentrations at 15 and 30 minutes post meal were not 203 
significantly increased versus baseline. In fact concentrations at 30 minutes appeared slightly decreased, 204 
but this change was not significant. Feelings of hunger subsided after the meal and participants were 205 
least hungry at 15 minutes post meal before steadily feeling hungrier with time (Figure 1 B). When 206 
comparing the pattern of prouroguanlyin concentrations and hunger levels there was no indication that 207 
prouroguanylin concentrations increased as hunger subsided and there was not a significant correlation 208 
between hunger and prouroguanylin concentrations. 209 
3.2 Study 2- The effect of a 725 kcal meal on plasma Prouroguanylin concentrations in males                               210 
Seven males completed this study. The mean BMI was 22.6 kg/m2 ± 2.0 with a range between 20.3 and 211 
25.1 kg/m2. The mean age was 28.9 years ± 11.2 with a range between 21- 51 years. Following the meal 212 
there was a significant increase in mean plasma Prouroguanylin concentrations at 120 minutes (P<0.01, 213 
0 versus 120 minutes) (Figure 2 A).  There were no significant changes at any other time point. When 214 
percentage change from baseline (0 minutes) was calculated for each time point and compared to the 215 
response seen in study 1 (1451kcal meal) (Figure 2 B), there was a significant interaction between time 216 
and meal (P<0.05), but examining individual time points and peak level, the difference between the two 217 
meals fell just short of being significant (Peaks, 1451 kcal 172.4%± 49.7 versus 725 kcal, 129.2%± 218 
20.6;  P= 0.055).  219 
3.3 Study 3- The effect of a 722.5 kcal carbohydrate rich breakfast on plasma Prouroguanylin 220 
concentrations in males and females of a healthy weight and those who are overweight/ with obesity.                                                        221 
10 males and 8 females were recruited for this study. The mean BMI was 25.1 kg/m2 ± 4.3 with a range 222 
between 20.5 and 39.8 kg/m2. The mean age was 35.9 years ± 17.7.  When data were split into BMI < 223 
25 kg /m2 (healthy weight) versus BMI >25 kg/m2 (overweight and with obesity) the mean BMIs were 224 
22.4 kg/m2 ± 1.2 and 28.5 kg/m2 ± 4.5 respectively. The mean ages in each group were almost identical 225 
(healthy weight 36.1±19.3 years and overweight and with obesity 35.6±15.4 years). 226 
When all data from participants were analysed as a single group plasma prouroguanylin concentrations 227 
were significantly decreased versus fasting (0 minutes) at 30 minutes post meal, (P<0.05, 0 versus 30 228 
minutes) and increased at 120 minutes after the meal (P<0.01, 0 versus 120 minutes) (Figure 3 A).  229 
There were no significant changes 0 versus 60 minutes. When data were split by BMI < 25 kg /m2 230 
(healthy weight) versus BMI >25 kg/m2 (overweight and with obesity), fasting concentrations (time 0) 231 
were significantly lower in the group who were overweight/with obesity (P< 0.05) (Figure 3 B), but 232 
there were no differences at post meal time points. In fact when analysing the percentage change from 233 
pre meal fasting concentrations (time 0) to peak concentrations the change was similar between groups. 234 
When data were split by sex there was no significant difference in prouroguanylin concentrations, 235 
however groups were not perfectly matched with males having a higher mean BMI (26.1 kg/m2 versus 236 
24.0 kg/m2). 237 
To compare to study 2 we then selected males only with a BMI under 26 kg /m2. The mean BMI was 238 
24.1 kg/m2 ± 2.0 with a range between 22.2 and 25.8 kg/m2 (n= 9).  There was no significant difference 239 






4. Discussion 246 
We have demonstrated that prouroguanylin concentrations are significantly increased after regular size 247 
meals (725kcal) as well as following very large meals (1451 kcal). However, we found the rise is 248 
delayed and does not follow the same pattern as self-reported hunger levels; prouroguanylin 249 
concentrations remain constant or are slightly decreased up to 30 minutes after a meal, then steadily 250 
rise, remaining at, or close to peak concentrations 120 minutes after a meal. Fasting prouroguanylin 251 
concentrations are lower in the group who were overweight/ with obesity versus those of a healthy 252 
weight, but post meal changes in hormone concentrations are similar in each group. Finally, changing 253 
the carbohydrate, fat or salt content of the meal did not appear to affect the post meal increase in 254 
hormone concentrations. 255 
Prouroguanylin, is the prohormone and circulating form of the gut hormone uroguanylin (24)(25)(11). 256 
When we started this study a single previous study had reported prouroguanylin concentrations rise 257 
after a large meal peaking at 45 minutes post meal in healthy adult males (11). In contrast we found 258 
following a fairly similar meal concentrations did not significantly change from fasting concentrations 259 
until 60 minutes after a meal, peaking at 90 minutes and remaining at similar concentrations by 120 260 
minutes, our final time point. The reasons for the difference in findings are currently unclear. An 261 
obvious difference between the two studies is the immunoassays used to measure prouroguanylin. We 262 
used a commercially available two site ELISA produced by Biovendor. We chose this assay as it had 263 
been previously assessed and validated for the measurement of prouroguanylin (23). Valentino et al. 264 
(11) used a one site ELISA they developed that is not commercially available. There has been limited 265 
characterisation of prouroguanylin and uroguanylin in circulation. There may be breakdown 266 
products/inactive forms of prouroguanylin or indeed multiple active forms of the hormone as is the case 267 
for several other gut hormones (26)(27)(28). Immunoassay’s can often detect multiple forms of peptide 268 
hormones, including breakdown products that have only lost one or two amino acids compare to the 269 
full hormone (28)(26)(29)(30). Thus, while we know both ELISAs detect intact prouroguanylin, we do 270 
not know if either assay is detecting other as yet unknown forms of prouroguanylin or breakdown 271 
products. A better understanding of circulating prouroguanylin and uroguanylin and their metabolites 272 
would aid further investigation in this area.  273 
Recently a study in adolescents (aged 14-17 y) has examined prouroguanylin concentrations after meals 274 
(800-1100 kcal) (19). Prouroguanylin concentrations were assayed using the same Biovendor ELISA 275 
used in our studies. The post meal changes in prouroguanylin observed were similar to our study; they 276 
reported a decrease immediately after a meal, with concentrations then rising up to their final time point, 277 
90 minutes post meal. This suggests regulation of prouroguanylin in adolescents and adults is similar, 278 
and that the different prourguanylin assays used are the most likely cause of the discrepancy between 279 
our study and Valentino et al.’s study (11). 280 
 281 
Although the choice of ELISA is the most logical explanation of differences between results in our 282 
study and Valentino et al.’s, there were small differences in the meals given. Meals in both studies were 283 
high calorie, high fat and sugar, unhealthy breakfasts, but the macronutrient content did differ; our study 284 
meal had higher fat (48% versus 35%) and lower carbohydrate (36% versus 54%). It may be that this 285 
difference affected the post meal response. However, given the higher carbohydrate and lower fat 286 
content of our meal in study 3 did not lead to an earlier peak in prouroguanylin concentrations we feel 287 
it is unlikely this accounts for the difference.  288 
A final possible but less likely explanation for the differences between the two studies is the 289 
demographic of the participants. The mean BMI of the participants was almost identical between the 290 
two studies (23.2 versus, 23.4 kg/m2). The participants in Valentino et al.’s study were older; 31.7 years 291 
versus 23.5 in our study 1 (1451 kcal). However, in our study 2 the mean age was 28.9 years, yet the 292 
pattern of prouroguanylin concentrations we observed was similar, suggesting this magnitude of 293 
difference in age is unlikely to affect prouroguanylin concentrations.   294 
A 1451 kcal meal is large and represents 58% of the recommended daily calories for men and 72.5 % 295 
for women. Before targeting the uroguanylin system for weight loss through diet or pharmacology it is 296 
important to know whether smaller meals, more typical of real life, cause release of this hormone. We 297 
went on to show for the first time in adults that smaller 722.5-725 kcal meals lead to a significant 298 
increase in Prouroguaylin concentrations 120 minutes post meal. In study 2 (725 kcal) the meal was 299 
identical to study 1 (1451 kcal) except all portions were halved in size and both studies just included 300 
males. A similar pattern of post meal release was observed except changes did not become significant 301 
until the 120 minute time point. When comparing the percentage change from baseline concentrations 302 
in each study there was a significant interaction between time and meal with there appearing to be a 303 
greater postprandial rise following the larger meal. However, there was not a significant effect at any 304 
individual time point, and peak concentrations fell just short of being significantly different (p=0.055). 305 
Therefore, while our results lead us to speculate that prouroguanylin concentrations, like other gut 306 
hormones (29)(31), rise or fall in proportion to the calories consumed, we cannot confirm this pattern. 307 
We acknowledge that as our two studies were separate experiments with different participants they may 308 
not be ideal in terms of design to answer this question. Instead a paired or repeated measures design 309 
where the same participants are measured following each meal is needed.  310 
At present we do not know whether the post meal changes in prouroguanylin concentrations we 311 
observed in study one or study two are sufficient to have any physiological effect. The reported EC50 312 
for uroguanylin at GUCY2C is  500nM (32). The mean post meal changes in concentrations we report 313 
in study one were approximately 1000 pg/ml which equates to 83 pM. This is some way below the 314 
EC50 and casts doubt on whether changes would be sufficient to affect GUCYC signalling. However, 315 
it is hypothesised prouroguanylin is processed to active uroguanylin in tissues such as the hypothalamus 316 
(11) and we do not know the uroguanylin concentrations that may accumulate in these tissues. 317 
Furthermore, circulating post meal changes of other gut hormones such as PYY (33)  fall along way 318 
below the reported EC50 (34), yet they are thought to play a role in the regulation of feeding.  To help 319 
us understand the significance of post meal changes in prouroguanylin, it important for future studies 320 
to establish the circulating concentrations required to elicits any potential effects on body mass or 321 
feeding. 322 
Our final study recruited both sexes and examined prouroguanylin release following a mixed 323 
macronutrient high carbohydrate meal (722.5 kcals). This meal contained cereal and fruit, and although 324 
still relatively high energy for a breakfast could be consider closer to a traditional view of a healthy 325 
breakfast (20). In accord with the first two studies  prouroguanylin concentrations were increased versus 326 
baseline 120 minutes post meal. However, in this study hormone concentrations were suppressed versus 327 
baseline 30 minutes after the meal. This result was not entirely unexpected as in study 1 a similar pattern 328 
was observed but the reduction at 30 minutes was smaller and non significant. While generally in accord 329 
with the pattern observed in the first two studies, this is a clear difference to the pattern observed by 330 
Valentino et al.  However, results were similar to those observed by Di Guglielmo et al. (19) in 331 
adolescents. This early post meal change could relate to urogunaylin’s role within the gut regulating 332 
fluid and electrolyte balance (8)(35) or gut motility. Based on evidence from the guanylate cyclase 333 
agonist, Linaclotide, unlike other gut hormones such as PYY (36)(37), uroguanylin is likely to speed 334 
up rather than slow down gastrointestinal transit (38).   335 
Study 3 also examined the effect of BMI on prouroguanylin concentrations. In accord with Rodríguez 336 
et al. (17), the group who were overweight/ with obesity had lower fasting prouroguanylin 337 
concentrations. However, there was not a significant difference between the groups at later time points. 338 
In fact, in contrast to other gut hormones such as PYY (39)(29), post meal changes in prouroguanylin 339 
were at least equal in the group who were overweight/ with obesity, with a trend towards a greater rise 340 
in concentrations (0 versus 120 minutes) in the group who were overweight/ with obesity. This finding 341 
is interesting as the reduced post prandial release of PYY and suppression of ghrelin in those with 342 
obesity has been hypothesised to be important in post meal satiety (29)(31). Based on our results the 343 
same hypothesis could not be related to  prouroguanylin. Furthermore, given some rodent studies report 344 
uroguanylin administration suppresses feeding (13)(11), the robust post prandial response observed in 345 
our group who were overweight/with obesity may suggest potential in targeting prouroguanylin, 346 
through diet or pharmacological activators of nutrient receptors to treat obesity. However, we are 347 
currently still some way from knowing whether prouroguanylin is a suitable target for obesity therapies. 348 
For example, our study suggests prouroguanylin is not involved in the initial suppression of hunger 349 
after a meal, but it still could be involved in later feeling of satiety and this needs to be investigated.  350 
Our results examining the effect of BMI on prouroguanylin are again comparable to those recently 351 
reported by Di Guglielmo et al. in adolescents (19). These results are at odds with a study in rodents 352 
that suggested diet induced obesity suppressed post prandial uroguanylin secretion in mice (14).  Further 353 
investigation is needed to see if there is a species difference or perhaps whether only specific diets or 354 
more severe obesity affect post meal secretion. Given its proposed role in body mass regulation it is 355 
possible the decreased fasting concentrations of prouroguanylin observed in obesity may make it harder 356 
for people to lose weight. The data from rodents (14) suggests obesity leads to low prouroguanylin 357 
concentrations, rather than being the initial cause. 358 
 Rodents studies have demonstrated urogunaylin secretion and expression are regulated by leptin (15); 359 
with urogunaylin lower following leptin administration or fasting.   We would predict our healthy BMI 360 
group would have lower leptin concentrations than the group who were overweight/ with obesity and 361 
this may contribute to the difference in the fasting prouroguanylin concentrations. However, higher 362 
leptin or possible leptin resistance in the adolescents and adults who were overweight/with obesity, 363 
studied by Di Guglielmo et al. (19) and us does not appear to affect post meal changes. 364 
Some recent studies have suggested variation in the uroguanylin system  between the sexes (19) (40).  365 
One study reported a negative correlation between plasma fasting prouroguanylin concentration and 366 
BMI in girls, but a positive correlation in boys (40).  Another study found female but not male 367 
adolescents with obesity had lower prouroguanylin concentrations (19). In our study numbers were too 368 
small to examine the effect of BMI in each sex. Splitting our group from study 3 by sex alone suggested 369 
there was no significant difference in prouroguanylin concentrations between males and females. 370 
However, our groups weren’t ideally matched as our male group had a higher mean BMI and this may 371 
have affected the results of our comparison. It is also possible that in females prouroguanylin 372 
concentrations vary across the menstrual cycle or are affected by contraception or childbirth. We 373 
acknowledge that while we excluded those who were pregnant, breastfeeding or had recently given 374 
birth, we did not record or control for other factors relating to the female reproductive system. Further 375 
larger studies considering these factors are required to clarify whether there are differences in 376 
prouroguanylin concentrations between adult males and females. 377 
Finally, we carried out a post-hoc analysis comparing the percentage changes from baseline following 378 
meals given in study 2 and study 3. For this we only included male subjects from study 3 within the 379 
same BMI range as subjects from study 2. The meal given in study 2, versus study 3, had much higher 380 
fat (48% versus 12.7%) and salt (2.1 grams versus 0.4 grams) content, and lower carbohydrate content 381 
(36% versus 73.9%).  Despite these differences there was no statistically significant difference in the 382 
overall post meal pattern and the magnitude of the change from baseline to 120 minutes was very similar 383 
(23% vs 28%). This suggests that variation in fat, carbohydrate and salt content of the meals did not 384 
have a major influence on post prandial release. Given uroguanylin’s role in salt regulation (24)(41), it 385 
could be hypothesised, that dietary salt may affect circulating prouroguanylin concentrations. However, 386 
our findings related to dietary salt are in accord with a recent publication demonstrating dietary salt 387 
influenced urogunaylin RNA expression in the kidney (22), but not the proximal small intestine (the 388 
predicted source of circulating prouroguanylin).  389 
4.1 Conclusion   390 
This is the first study to examine prouroguanylin release in adults of a healthy weight and those who 391 
are overweight/with obesity following large and medium sized meals. The results suggest that 392 
immediately post meal prouroguanylin concentrations remain stable or decrease, then increase steadily 393 
to above fasting concentrations, remaining at, or close to peak concentrations 120 minutes after 394 
ingestion of a meal. Fasting concentrations are lower in those who are overweight/with obesity, but the 395 
magnitude of the post meal rise of the hormone is similar. These results are in accord with recent 396 
observations in healthy weight and adolescents with obesity (19). Our study suggests total calorie 397 
content of a meal may influence prouroguanylin concentrations, but variation of fat, carbohydrate and 398 
salt content do not appear to have a major effect. However, these were examined using a post-hoc 399 
analysis of different experiments, so need to be confirmed by further studies. Overall our study has 400 
increased understanding of the regulation of prouroguanylin and may help assess whether it is a viable 401 
target for obesity therapies. 402 
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Figure Legends 566 
Figure 1. Plasma prouroguanylin concentrations A, and visual analogue hunger scores, B, from healthy 567 
males (n=7) pre (0 minutes) and post a 1451 kcal. Data presented are the mean with error bar 568 
representing the standard deviations. Repeated ANOVA was used with post hoc ,Dunnett’s test to see 569 
if there was a difference between individual time points ( *  =P < 0.05 versus pre meal, 0 minutes, ** = 570 
P<0.01 versus pre meal, 0 minutes.) 571 
Figure 2. A. Plasma prouroguanylin concentrations from healthy males (n=7) pre and post a 725 kcal. 572 
Data presented are the mean with error bar representing the standard deviations. Repeated ANOVA was 573 
used with post hoc Dunnett’s test to see if there was a difference between individual time points (** = 574 
P<0.01 versus 0 minutes.). B. Comparison of the percentage change from fasting (Time =0) at each post 575 
meal time point, following the 725 kcal meal versus the 1451 kcal meal (n=7 for each study). 576 
Figure 3. Plasma prouroguanylin concentrations following a 722.5 kcal high carbohydrate meal, from 577 
a mixed sex group including, 9 healthy weight adults and 9 overweight or with obesity.   Data presented 578 
are the mean with error bar representing the standard deviations. A Includes all participants as a single 579 
group. Repeated ANOVA was used with post hoc Dunnett’s test to see if there was a difference between 580 
individual time points (*  =P < 0.05 versus 0 minutes, ** = P<0.01 versus 0 minutes.). B Shows the 581 
data split into the participants with a healthy BMI (n=9) and those who were overweight or with obesity 582 
(n=9). Fasting concentrations alone were significantly different between groups (* =P<0.05). But there 583 
was no overall effect of BMI group when data were analysed by two way ANOVA of repeated 584 
measures. C Study 2 versus Study 3, Males BMI under 26 kg /m2 only. Comparison of the percentage 585 
change from fasting (Time =0) at each post meal time point, following the 722.5 kcal high carbohydrate 586 
meal (study 3) versus the 725 kcal high fat meal (study 2) (n=7-9). 587 
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